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INTRODUCTION
Leukemia frequently gives rise to otologic signs and symptoms in
several ways, the most common being the infiltration of leukemic
cells, which results in small hemorrhages and infections of the
ear (1, 2). Very rarely, however, otologic symptoms result from
myeloid sarcoma, which is a discrete mass composed of malig-
nant myeloid cells.
To date, there have been only a few case reports of myeloid
sarcoma involving the temporal bone. Five such patients were
recently seen and treated at our institution. In this report, we
examine the clinical features of myeloid sarcoma involving the
temporal bone by comparing its clinical features with those of
metastatic lesions of the temporal bone and the lesions originate
from non-systemic malignancy. All of the clinical features of these
five cases are summarized in Table 1.
CASE REPORTS
Case 1
A 21-yr-old male presented with left-side ear fullness of 1 month’s
duration. He had been previously treated for otitis externa at a
local clinic. Six years earlier, he was diagnosed with acute myeloid
leukemia (M1) and underwent bone marrow transplantation after
achieving complete remission. On physical exam, the posterosu-
perior part of the external auditory canal (EAC) showed marked
bulging and the tympanic membrane was not visible. Pure-tone
audiometry showed a left-side conductive hearing loss of 35 dB.
A computed tomography (CT) scan of the temporal bone showed
a soft-tissue density filling the mastoid antrum and middle ear. The
soft tissue had eroded the mastoid cortex and seemed to extend
to the wall of the EAC. Magnetic resonance imaging (MRI) of the
temporal bone showed similar results (Fig. 1). A pathologic study
of the EAC mass confirmed the diagnosis as myeloid sarcoma.
Bone marrow biopsy showed relapsing leukemia. Unfortunately,
the patient died of septic shock 1 month into a course of chemo-
therapy.
Case 2
A 47-yr-old male with left facial palsy and retroauricular swelling
was referred to our institution after being seen at another hospi-
tal for facial palsy, which had begun 3 months earlier. However,
his symptoms had not improved and retroauricular swelling had
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developed on the same side 1 month before he came to our atten-
tion.
One year earlier, he was diagnosed with acute myeloid leuk-
emia (AML), type M2, obtaining complete remission after che-
motherapy. He denied a history of trauma, upper respiratory
tract infection, or previous facial palsy. On physical exam, the
left tympanic membrane was intact, but the posterior wall of the
EAC bulged and a retroauricular swelling of about 10 cm was
seen. MRI of the temporal bone showed a poorly demarcated,
homogenously enhancing soft-tissue density filling the subcuta-
neous layer over the mastoid cortex, and forming a large mass
around the mastoid tip (Fig. 2). The mastoid antrum was partially
filled with the soft-tissue density. However, a connection between
the mastoid and the subcutaneous mass could not be determined,
nor was there evidence of facial nerve invasion by the mass. Bi-
opsy to evaluate the mass confirmed a diagnosis of myeloid sar-
coma. Bone marrow biopsy studies revealed no evidence of leu-
kemia relapse. During radiotherapy, the facial palsy improved
temporarily but then worsened and a relapse of leukemia was
diagnosed on a repeat bone marrow biopsy after 3 months. Dur-
ing treatment for relapsing leukemia, the patient died from sep-
tic shock.
Case 3
A 12-yr-old boy visited our clinic due to a left-side retroauricu-
lar swelling of 2 months duration. He had been diagnosed with
AML (M2) 1 yr earlier and had achieved complete remission of
the disease after chemotherapy. While awaiting allogeneic bone
marrow transplantation, he underwent MRI of the brain, which
illustrated a homogeneously enhancing mass occupying almost
the entire temporal bone. The meninges of the fusiform gyrus
in the temporal lobe, near the mass, showed pachymeningeal
enhancement, strongly suggesting intracranial invasion of the
mass. Bone marrow biopsy revealed a relapse of the leukemia.
Re-induction chemotherapy was initiated and after the first cycle
of chemotherapy the leukemia remitted and the size of the my-
Case Age/ Type of
Presenting symptoms Interval* Involvement site
Type of
Result
No. gender leukemia treatment
Table 1. Summary of the clinical characteristics of the 5 cases
*Interval between the beginning of symptoms and the diagnosis.
AML: acute myeloid leukemia; EAC: external auditory canal; M: mastoid; ME: middle ear; PB: petrous bone; CTx: chemotherapy; RTx: radiotherapy; DD: died
of disease; NED: no evidence of disease.
1 21/M AML M1 Ear fullness, EAC obstruction 1 month EAC, M, ME CTx DD
2 47/M AML M2 Facial palsy, retroauricular swelling 3 months EAC, M, ME RTx+CTx DD
3 12/M AML M2 Retroauricular swelling 2 months M, PB, meninges CTx NED
4 16/M AML M2 Ear fullness, otalgia 2 months Clivus, PB, M, ME RTx+CTx DD
5 15/F AML M2 Ear fullness, otalgia 5 months Clivus, PB, paranasal sinuses RTx+CTx DD
Fig. 1. Radiologic evaluation of myeloid sarcoma (case 1) showing erosion of the mastoid cortex (arrow) and extension of the mass into the exter-
nal auditory canal.
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eloid sarcoma decreased rapidly. The patient received another
3 cycles of chemotherapy, and intrathecal chemotherapy once.
Follow-up brain MRI showed a tiny, non-enhancing mass at the
mastoid, and we concluded that the myeloid sarcoma had dis-
appeared. He subsequently underwent allogeneic bone marrow
transplantation and, at this writing, is alive without experienc-
ing any further problems.
Case 4
A 16-yr-old male presented with right-side otalgia and fullness
of both ears. He had been diagnosed with a relapse of AML (M2)
5 months earlier for which he underwent chemotherapy, but his
bone marrow showed incomplete disease remission. The right
tympanic membrane appeared to be inflamed and the left one
turbid. Pure-tone audiometry showed a bilateral conductive hear-
ing loss of 20 dB. The patient was prescribed antibiotics empiri-
cally for the otitis media, but the symptoms and middle-ear effu-
sion did not resolve after 1 month of conservative treatment. MRI
of the temporal bone was conducted to determine whether a le-
sion was causing the middle-ear effusion. T1-weighted post-con-
trast images showed a heterogeneously enhancing mass invading
the clivus and both petrous apexes, mastoid cavities, and middle
ears. Secondary otitis media was thought to be due to the mass.
Since the patient already had a history of relapsed leukemia and
his general condition was very poor, the mass was not biopsied
and was regarded as myeloid sarcoma. Despite treatment with
additional craniocephalic radiotherapy, the myeloid sarcoma did
not decrease in size. He died of pulmonary hemorrhage asphyx-
ia 2 months later.
Case 5
A 15-yr-old female previously diagnosed with AML (M2) present-
ed with bilateral otalgia during the course of re-induction chemo-
therapy. Remission of the leukemia was not achieved following
induction chemotherapy. The right tympanic membrane was am-
ber-colored and the left tympanic membrane inflamed. She was
diagnosed with acute otitis media and treated accordingly. After
1 month of conservative treatment, the patient presented with
mild autophonia on the right side. However, both tympanic me-
mbranes were normal and pure-tone audiometry showed no ab-
normality. Her leukemia was still refractory to re-induction ch-
emotherapy, but her general condition did not worsen. Four mo-
nths later, she presented with intractable headache that did not
respond to analgesics. Brain MRI showed a huge mass on the
sphenoid clivus that invaded the left petrous apex, while enclosing
the internal auditory canal, the left occipital condyle, sphenoid
sinus, ethmoid sinus, and nasopharyngeal mucosa. Based on the
patient’s clinical history, the mass was presumed to be myeloid
sarcoma. To relieve her symptoms, brain radiotherapy was car-
ried out but she expired due to exacerbation of the leukemia. 
DISCUSSION
Ear involvement has been described in chronic and in acute le-
ukemia. Berlinger (3) reported that leukemic infiltration of the
middle-ear cleft occurs in one-third of patients and tends to fol-
low the mucosal folds to the ossicles and intratympanic muscles,
and into the tympanic membrane. Among 45 temporal bones
from 25 leukemic patients, Paparella et al. (4) reported that 7
Fig. 2. Relatively homogenously enhanced myeloid sarcoma (case 2) is seen filling the left mastoid (asterisk) and the subcutaneous layer over
the mastoid cortex. It is uncertain whether there is a connection between the mastoid and the subcutaneous layer.
A B
* *patients (28%) had experienced clinical problems for which a
leukemic etiology could not be established, but 5 patients (20%)
had otologic complications directly attributable to the leukemia.
Not only malignant infiltrates but also hemorrhages and infec-
tions of the middle and inner ear result in otologic symptoms (1,
2). Biochemical changes affecting the sensitive structure of the
inner ear, such as vascular permeability changes or alterations in
the ion concentrations between the endolymph and perilymph,
may also lead to symptoms (1). Very rarely, otologic symptoms
result from myeloid sarcoma.
Myeloid sarcoma is characterized by the occurrence of one
or more tumor masses consisting of immature myeloid cells and
presenting at an extramedullary site (5). It may develop de novo
or concurrently with AML, myeloproliferative disorder, or my-
elodysplastic syndrome (5). The true incidence of myeloid sarco-
ma is not known (6) and, because of its rarity, large-scale stud-
ies are lacking. Recently, Pireli et al. (5) reported the character-
istics of myeloid sarcoma in an analysis of 92 patients. The com-
monest sites were skin (28.2%), lymph node (16.3%), testis (6.5
%), and intestine (6.5%). Bone involvement accounted for 3.25%
of the cases. Thus, myeloid sarcoma involving the temporal bone
is very rarely seen in clinical practice. 
Myeloid sarcoma is considered to be part of a systemic malig-
nancy. In this context, a comparison between the clinical features
of our five cases with those of metastatic lesions of the temporal
bone is justified, and will further our understanding of the unique
features of temporal bone myeloid sarcoma. Possible primary
sources of metastatic lesions to bone and thus to the temporal
bone are breast, lung, kidney, stomach, prostate, larynx, and thy-
roid (7). Gloria-Cruz et al. (8) analyzed 415 temporal bones from
212 patients with primary non-systemic malignant neoplasm. The
most common symptom was hearing loss (40.4%), followed by
vertigo (14.9%), facial palsy (14.9%), and tinnitus (12.8%); how-
ever, 36.2% of the patients were asymptomatic. In our series, 3
patients had hearing loss (60%), and 1 (20%) had facial palsy,
similar to the rates in patients with metastatic lesions. Two of our
patients had postauricular swelling and 1 had EAC swelling, nei-
ther of which frequently occurred in the presence of a metastat-
ic lesion. 
Myeloid sarcoma seems to involve the temporal bone more
randomly and diffusely than non-systemic malignancy, as report-
ed by Berlinger (3). However, there is a greater tendency of mas-
toid involvement. Four of our 5 patients (80%) had mastoid in-
volvement, as determined radiologically. There are very few pub-
lished case reports of myeloid sarcoma involving the temporal
bone. Most of them involved the mastoid, and the patients pre-
sented with symptoms related to mastoid involvement (2, 4, 9-
13). The predominance of the tumor in the mastoid cavity can be
explained by that fact that the latter is more vulnerable to har-
boring a mass than the hard petrous bone.
In non-systemic malignancy, Gloria-Cruz et al. (8) reported
that metastatic lesions commonly (82.9%) involved the petrous
apex, with the mastoid involved in 21 cases (27.6%), usually by
hematogenous spread. The authors stated that the hematogenous-
ly spreading tumor cells must first pass the petrous apex before
involving the mastoid (8). 
In leukemic infiltrations, Berlinger et al. (3) also reported that
the marrow space of the petrous apex was almost always invo-
lved. If pathologic testing of the entire temporal bone had been
possible in our patients, it might have revealed leukemic infil-
tration of the petrous apex; instead, there were 3 cases of radio-
logically confirmed petrous bone involvement.
Myeloid sarcoma is not easily diagnosed when the presenting
symptoms mimic otomastoiditis, especially since leukemia patients
are highly susceptible to bacterial, viral, or fungal infections (14).
Two of our patients with postauricular swelling (cases 2, 3) were
diagnosed easily within 1 month of their first visit to our clinic,
whereas one patient with persisting middle ear effusion (case 4)
was not diagnosed until 2 months, and another (case 5), whose
middle-ear effusion was resolved with antibiotics, was not diag-
nosed until 5 months after visiting our clinic. One patient with
EAC swelling (case 1) had been treated for otitis externa for 1
month before he was seen at our hospital. 
Biopsy is the most preferred diagnostic method but is not al-
ways feasible. A biopsy sample may be difficult to obtain, espe-
cially when the mass is in an anatomically difficult site such as
the petrous bone. Even if the mass is located in a site that is eas-
ily reached, biopsy is not feasible for patients with thrombocy-
topenia or acquired consumption coagulopathy (14).
Both CT scan and MRI are diagnostically very useful, but MRI
better reveals the exact extent of the tumor and potential inva-
sion of the cranial nerve or intracranial structure. Noh et al. (15)
analyzed radiologic features of myeloid sarcoma in 11 patients.
They concluded myeloid sarcoma is seen as homogenously en-
hancing and well demarcated mass with adjacent bony erosion
in CT and MRI images. And they added myeloid sarcoma should
be strongly considered in patients with myelogenous leukemia
even if the imaging appearance is non-specific to myeloid sarco-
ma. We observed relatively well demarcated mass in case 3, but
another 4 cases showed poorly demarcated lesion. And 3 of our
cases showed homogenously enhancing pattern. Our findings are
rather different from Noh’s results, but we think clinical history
of patient is also important to make a diagnosis.
Two of our patients were diagnosed by pathologic study, and
another by an imaging study and clinical history. All of the pa-
tients, who were not diagnosed by pathologic study, showed
relapsed or unresolved leukemia on bone marrow study. They
presented with a mass lesion, seen radiologically, and their symp-
toms did not resolve with antibiotics. In the patient described in
case 3, the mass was reduced by chemotherapy, thus confirming
the diagnosis. But, in cases 4 and 5, the leukemia did not respond
to chemotherapy and the clinical states of the patients rapidly
worsened. Autopsy was not performed. 
The single most important point in the diagnosis of temporal
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bone malignancy is suspicion. Physicians should be alert to the
patient’s symptoms. Maddox emphasized the symptom triad of
otalgia, periauricular swelling, and facial nerve paresis as being hi-
ghly suggestive of malignant involvement of the temporal bone. In
addition, physicians should not overlook those symptoms that
commonly accompany otomastoiditis, such as persisting effusion,
when the patient has a systemic or non-systemic malignancy (1).
There is no standard treatment for myeloid sarcoma, especial-
ly when it occurs de novo (5, 6); rather, treatment is similar to
that of systemic disease, as it is considered a manifestation of such.
When a patient with myeloid sarcoma has leukemia or relapsed
leukemia, combination chemotherapy for acute leukemia may
induce complete remission. Additional craniocephalic radiation
therapy is often considered when the disease persists after che-
motherapy (6, 14). Systemic chemotherapy also may induce com-
plete remission in the patient with de novo myeloid sarcoma (6,
16).
The prognosis of myeloid sarcoma is unfavorable. Pileri et al.
(5) reported that of the 67 patients for whom follow-up data were
available, 60 died from the disease (89.5%). Interestingly, all 7
survivors achieved complete remission of their myeloid sarcoma
following first-line therapy, in contrast to only 8 of the 60 patients
who died achieved complete remission. Bone marrow transplan-
tation resulted in longer survival than conventional therapy. Bas-
ed on these results, the authors strongly recommended that pa-
tients with myeloid sarcoma undergo high-dose therapies as a
front-line approach, as it seems to be the only chance to achieve
complete remission and to cure the disease. In our series, the
patient of case 3, who only achieved complete remission after
re-induction chemotherapy, was the only one to survive. 
Even though the prognosis of myeloid sarcoma is very poor,
it should be diagnosed as early as possible because early high-dose
therapies offer the only possibility of cure. Finally, in leukemic
patients, even in those in complete remission, physicians should
not overlook symptoms mimicking otomastoiditis and must bear
in mind the possibility of myeloid sarcoma.
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